Biolife Solutions Inc.

Dr. Clarke joined BioLife in 2007 and brings an extensive background in the field of low temperature biology. He has authored or co-authored several scientific papers detailing the effects of cold stress and freezing temperatures on cell survival. Dr. Clarke has been the Principal Investigator on multiple NIH SBIR funded grants. He holds a Ph.D. in Cellular and Molecular Biology from the State University of New York at Binghamton and performed his post-doctoral studies in the field of Cellular and Developmental Biology at Syracuse University Upstate Medical Center. In addition to directing our research and product development activities, Dr. Clarke has co-authored several of the Company's recent patent applications.

Dr. Nicoud served as an intellectual property and technology consultant for BioLife and joined the Company in September 2007. He has a strong background in transplantation medicine and preservation biology and holds a Ph.D. in Cancer Biology from Vanderbilt University and a B.S. in Biology from Saint Norbert College. He is a co-author of several of the Company's recent patent applications and manages our intellectual property portfolio and technology licensing activities.

Michael Rice has been President and Chief Executive Officer and a director of the Company since August 2006. From October 2004 to August 2006, Mr. Rice served as Sr. Business Development Manager for the Medical & Wireless Products Group at AMI Semiconductor, Inc. (NASDAQ: AMIS). Prior thereto, from October 2000 to October 2004 he served as Director of Marketing & Business Development, Western Region Sales Manager, and Director, Commercial Sales at Cardiac Science, Inc. (NASDAQ: CSCX); from May 1998 to October 2000 as Vice President, Sales and Marketing at TEGRIS Corporation; and from May 1986 to May 1998 in several sales and marketing roles at Physio Control Corporation.

Laurie Smith has served as Controller of the Company since September 2007. Prior to joining BioLife, she served as Finance Manager at Northstar Neuroscience, Inc., a public medical device company, from its inception in June 1999 to April 2007. Prior thereto, from August 1996 to July 1998 she served as Accounting Manager at Heartstream, Inc., and from August 1992 to June 1996 as Senior Accountant at Panlabs, Inc.

Principal of Advanced Cell and Gene Therapy, a consulting firm specializing in cell, gene, and tissue-based therapies. Dr. Burger works with clients in industry and academic centers worldwide, providing assistance in process development and validation, GMP/GTP manufacturing, GMP facility design and operation, regulatory affairs, technology evaluation, and strategic analysis.

Raymond Cohen joined the Board in May 2006. Mr. Cohen currently serves as Chief Executive Officer of Laguna Hills, CA-based Symphony Medical, Inc., a venture capital backed privately-held developer of biologic solutions for the treatment of cardiac conduction abnormalities. Mr. Cohen is also a director of Cardiac Science Corporation (NASDAQ: CSCX), where he served as Chief Executive Officer for nine years, and as Chairman from September 2005 through October 2006. Mr. Cohen also serves as a member of the Board of Directors of Syncroness, Inc., a privately-held contract engineering and product development firm based in Westminster, CO. He is a member of the Advisory Board for the College of Osteopathic Medicine, Western University of Health Sciences in Pomona, CA.

Andrew Hinson joined the Board in February 2007. He currently is the Vice President for Clinical and Regulatory Affairs for Symphony Medical, Inc., a venture capital backed privately-held developer of therapeutic biopolymer therapies for the treatment of heart failure and other cardiac abnormalities. Mr. Hinson has diverse experience in the cell and gene therapy markets and extensive experience managing clinical trials for new biologic based therapies for cardiac, neurologic, and gastrointestinal applications.

Dr. Delaney is the Director of the Cord Blood Research and Transplant Program at Fred Hutchinson Cancer Research Center (FHCRC) and Seattle Cancer Care Alliance (SCCA). She is an attending physician at Seattle Children's Hospital, Assistant Member of the Clinical Research Division of FHCRC and Assistant Professor at the University of Washington School of Medicine. Dr. Delaney's research interests include hematopoietic stem cell regulation and the development of novel and clinically feasible ex vivo expansion systems for hematopoietic progenitor cells. Her goal is to improve the outcome of patients in need of a cord blood transplant. Dr. Delaney is principal investigator on five FHCRC clinical trials investigating the use of single or double unrelated donor umbilical cord blood grafts as an alternative source of stem cells for hematopoietic cell transplant, including a multi-center protocol investigating the use of single versus double unrelated donor umbilical cord blood grafts as source of stem cells for hematopoietic cells.

Darin Weber, Ph.D, is a leading regulatory expert for cellular and tissue based products, and a former FDA cellular therapy reviewer. Dr. Weber's knowledge of the regulatory landscape for cell and gene therapy is extensive and directly relevant to our business since the Company's preservation solutions are a critical process component in several active clinical trials for new cellular therapy products.

Dayong Gao, Ph.D, is a professor of biomedical engineering at the University of Washington in Seattle. Dr. Gao has been actively engaged in cryopreservation research for more than 20 years, having authored over 130 peer-reviewed journal articles on cryopreservation.

Howard S. Breslow has served as a director of the Company since July 1988. He has been a practicing attorney in New York City for more than 40 years and is a member of the law firm of Breslow & Walker, LLP, New York, New York, which firm serves as general counsel to the Company.

Shelly Heimfeld, Ph.D, is the Director of the Cellular Therapy Laboratory at the Fred Hutchinson Cancer Research Center in Seattle, and also the President of the International Society of Cellular Therapy. Dr. Heimfeld is internationally recognized for research in hematopoietic-derived stem cells and the development of cell processing technologies for improved cancer therapy.

Thomas Girschweiler joined the Board in 2003. Mr. Girschweiler has been engaged in corporate financing activities on his own behalf since 1996. From 1981 to 1996 he was an investment banker with Union Bank of Switzerland. Mr. Girschweiler was graduated at the Swiss Banking School.